Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) have a negative impact on employment, found a study published in the journal Multiple Sclerosis and Related Disorders. “The ...

The US Food and Drug Administration (FDA) approved Panzyga, manufactured by Octapharma AG, for the treatment of PI and ITP in 2018 and for CIDP in adults in 2021. Octapharma commercializes Panzyga ...

Although nerve conduction studies are the gold standard for diagnosing chronic inflammatory demyelinating polyneuropathy (CIDP), imaging techniques such as ultrasound and magnetic resonance imaging ...

Only 2 disease-modifying idiopathic pulmonary fibrosis (IPF) therapies have been approved by the US Food and Drug Administration (FDA) as of June 2025. They do not stop or cure the disease, so the use ...

RPL30 showed the highest fold-change difference in patients with PBC compared to healthy people. Anti-RPL30 seems to be a promising biomarker for the diagnosis of primary biliary cholangitis (PBC) ...

The studies indicated comparable growth trends regardless of whether therapy was initiated before or after age 5. Vosoritide, a once-daily injectable therapy, may improve growth outcomes in children ...

The study found no significant association between genomic ancestry and immune tolerance induction success or peak inhibitor titers. Certain ancestries are linked to specific genetic patterns in ...

Hemophilia can cause a lot of confusion for patients and their families. We don’t always know where to draw the line regarding what we can and can’t do. On one side, we want to be able to enjoy life ...

Motor function significantly improved, with Motor Function Measure-32 scores increasing by 2.3% at 1 year and by 2.6% at 2 years in adult patients with spinal muscular atrophy treated with risdiplam.

Therapy with Bruton tyrosine kinase inhibitors in CLL was associated with a reduced risk of invasive candidiasis and aspergillosis. These findings from a large, retrospective cohort study highlight ...

Patients with B-ALL requiring third-line treatment received blinatumomab-containing regimens in 36% of cases, with 27% of those representing blinatumomab retreatment. A significant proportion of ...

The majority of patients (around 75%) have already been recruited at 172 sites. The protocol of a phase 3 clinical trial testing overall survival in patients with intermediate-2 or high-risk ...